Cover Image

Insulin-like growth factor binding protein 2 (IGFBP-2) as prognostic parameter in infarct-related cardiogenic shock

Background - Cardiogenic shock (CS) caused by acute myocardial infarction (AMI) is a critical condition with high mortality rate. Insulin-like growth factor binding protein 2 (IGFBP-2) is dysregulated in cardiovascular diseases. The purpose of the present study was to investigate the prognostic valu...

Full description

Saved in:
Bibliographic Details
Main Authors: Masyuk, Maryna (Author) , Wernly, Bernhard (Author) , Kelm, Malte (Author) , Freund, Anne (Author) , Pöss, Janine (Author) , Desch, Steffen (Author) , Schneider, Steffen (Author) , Akın, Ibrahim (Author) , Fürnau, Georg (Author) , Ceglarek, Uta (Author) , Schemmelmann, Mara (Author) , Isermann, Berend (Author) , Gerdes, Norbert (Author) , Schrage, Benedikt (Author) , Zeymer, Uwe (Author) , Büttner, Petra (Author) , Thiele, Holger (Author) , Jung, Christian (Author)
Format: Article (Journal)
Language:English
Published: 15 January 2026
In: International journal of cardiology
Year: 2026, Volume: 443, Pages: 1-6
ISSN:1874-1754
DOI:10.1016/j.ijcard.2025.133961
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ijcard.2025.133961
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0167527325010046
Get full text
Author Notes:Maryna Masyuk, Bernhard Wernly, Malte Kelm, Anne Freund, Janine Pöss, Steffen Desch, Steffen Schneider, Ibrahim Akin, Georg Fürnau, Uta Ceglarek, Mara Schemmelmann, Berend Isermann, Norbert Gerdes, Benedikt Schrage, Uwe Zeymer, Petra Büttner, Holger Thiele, Christian Jung
Description
Summary:Background - Cardiogenic shock (CS) caused by acute myocardial infarction (AMI) is a critical condition with high mortality rate. Insulin-like growth factor binding protein 2 (IGFBP-2) is dysregulated in cardiovascular diseases. The purpose of the present study was to investigate the prognostic value of IGFBP-2 in patients with AMI-CS. - Methods - This study is a post-hoc analysis of the randomized multicentre CULPRIT-SHOCK trial. IGFBP-2 levels were measured in serum samples from 423 patients using commercially available enzyme-linked immunosorbent assay (ELISA) kits. Associations of IGFBP-2 with 30-day and one-year mortality were investigated. - Results - Median IGFBP-2 concentration was 415 ng/ml (IQR 274-699 ng/ml). Patients with IGFBP-2 ≥ median demonstrated higher 30-day (54 % vs. 37 %; p < 0.001) and one-year mortality (60 % vs. 42 %; p < 0.001) compared to the < median group. Higher IGFBP-2 concentrations were associated with increased 30-day and one-year mortality, irrespective of it being analysed as continuous or categorical variable (per 100 ng/ml IGFBP-2, hazard ratio (HR) 1.06; 95 % confidence interval (CI) 1.04-1.09; p < 0.001, respectively; IGFBP-2 ≥ vs. < median, HR 1.70, 95 % CI 1.23-2.35, p = 0.001 and HR 1.72, 95 %CI 1.27-2.33, p < 0.001). Furthermore, IGFBP-2 ≥ median was associated with increased 30-day (HR 1.70; 95 %CI 1.23-2.35; p = 0.001) and one-year mortality (HR 1.72; 95 %CI 1.27-2.33; p < 0.001), even after adjustment for established prognostic factors. - Conclusions - In AMI-CS, elevated levels of IGFBP-2 were associated with higher mortality at 30 days and one year after admission. IGFBP-2 represents a promising prognostic biomarker and could add value to risk stratification in this high-risk patient cohort, potentially informing early clinical decision-making.
Item Description:Online verfügbar: 9.Oktober 2025, Artikelversion: Oktober 2025
Gesehen am 02.12.2025
Physical Description:Online Resource
ISSN:1874-1754
DOI:10.1016/j.ijcard.2025.133961

Similar Items